Long-Term Obligations - Additional Information (Detail)
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
|
|
|
|
May 13, 2024
USD ($)
shares
|
May 31, 2024
USD ($)
shares
|
Sep. 30, 2019
USD ($)
|
Sep. 30, 2024
USD ($)
$ / shares
shares
|
Sep. 30, 2023
USD ($)
|
Sep. 30, 2024
USD ($)
Days
$ / shares
shares
|
Sep. 30, 2023
USD ($)
|
May 08, 2024
USD ($)
shares
|
Dec. 31, 2023
USD ($)
|
Aug. 01, 2023
$ / shares
shares
|
Oct. 31, 2018
USD ($)
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents and investments |
|
|
|
$ 133,500,000
|
|
$ 133,500,000
|
|
|
|
|
|
Debt instrument convertible threshold consecutive trading days | Days |
|
|
|
|
|
5
|
|
|
|
|
|
Description of debt instrument convertible period |
|
|
|
|
|
during the five-business day period immediately after any five consecutive trading day period
|
|
|
|
|
|
Principal amount of notes used in conversion rate |
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
Debt instrument convertible threshold maximum percentage of product of last reported sale price of common stock |
|
|
|
|
|
98.00%
|
|
|
|
|
|
Percentage of redemption fee |
|
|
|
|
|
3.00%
|
|
|
|
|
|
Debt instrument exchange amount |
|
$ 148,000,000
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
|
|
Gain on extinguishment of debt |
|
|
|
$ 0
|
$ 0
|
$ 44,702,000
|
$ 0
|
|
|
|
|
Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Quarterly cash payments |
|
|
|
|
|
6.25%
|
|
|
|
|
|
Secured Overnight Financing Rate [Member] | Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Rate margin |
|
|
|
|
|
9.25%
|
|
|
|
|
|
Base Rate [Member] | Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Rate margin |
|
|
|
|
|
3.00%
|
|
|
|
|
|
Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Prepayment premium |
|
|
|
|
|
5.00%
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
$ 2.25
|
|
Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Prepayment premium |
|
|
|
|
|
3.00%
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
$ 1.1
|
|
May 2024 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Warrants purchased | shares |
|
|
|
45,776,212
|
|
45,776,212
|
|
45,776,213
|
|
|
|
Exercise price | $ / shares |
|
|
|
$ 1.1
|
|
$ 1.1
|
|
|
|
|
|
Conversion price description |
|
|
|
|
|
The May 2024 Warrants are exercisable through May 13, 2029. If the closing price of our common stock exceeds two times the then current exercise price of the warrants, which is currently equal to $2.20, for 20 trading days during any 30 consecutive trading day period, we can require the holder to exercise the May 2024 Warrants.
|
|
|
|
|
|
May 2024 Warrants [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Warrants purchased | shares |
45,800,000
|
45,800,000
|
|
|
|
|
|
|
|
|
|
Percentage common stock outstanding |
|
|
|
19.99%
|
|
19.99%
|
|
|
|
|
|
May 2024 Warrants [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Percentage common stock outstanding |
|
|
|
4.99%
|
|
4.99%
|
|
|
|
|
|
Pre Funded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
|
|
Number of warrants unissued | shares |
|
|
|
0
|
|
0
|
|
|
|
|
|
Deferred Royalty Obligation [Member] | Level 3 [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Deferred royalty obligation at fair value |
|
|
|
$ 73,500,000
|
|
$ 73,500,000
|
|
|
$ 129,700,000
|
|
|
HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Maximum remaining amount |
|
$ 128,300,000
|
|
|
|
|
|
|
|
|
|
HealthCare Royalty Partners IV LP [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Warrants purchased | shares |
|
|
|
|
|
|
|
|
|
250,000,000
|
|
Revenue Interest Financing Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Debt issuance costs |
|
|
|
1,700,000
|
|
1,700,000
|
|
|
|
|
|
First investment amount |
|
|
$ 135,000,000
|
|
|
|
|
|
|
|
|
Bifurcation of embedded derivatives |
|
|
|
$ 263,300,000
|
|
$ 263,300,000
|
|
|
|
|
|
Aggregate Royalties |
|
|
$ 263,300,000
|
|
|
|
|
|
|
|
|
Revenue Interest Financing Agreement [Member] | HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Repayment terms |
|
|
|
|
|
term may be shortened or extended depending on actual worldwide net product sales and upfront payments, milestones, and royalties. The repayment period expires on the earlier of (i) the date in which HCRx has received cash payments totaling $263.3 million or (ii) the legal maturity date of October 1, 2031. If HCRx has not received total payments equal to $263.3 million by September 2031, we will be required to pay an amount equal to $135.0 million plus a specific annual rate of return less payments previously paid to HCRx. In the event of a change of control, an event of default, including, among others, our failure to pay any amounts due to HCRx, insolvency, our failure to pay indebtedness when due, the revocation of regulatory approval of XPOVIO in the U.S. or our breach of any covenant contained in the Amended Revenue Interest Agreement and our failure to cure the breach within the prescribed time frame, we are obligated to pay HCRx an amount equal to $263.3 million less payments previously paid to HCRx.
|
|
|
|
|
|
Amended Revenue Interest Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount |
|
135,000,000
|
|
|
|
|
|
|
|
|
|
Revenue Interest Agreement and Amended Revenue Interest Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Debt instrument interest rate |
|
|
|
16.08%
|
|
16.08%
|
|
|
|
|
|
Revenue Interest Agreement and Amended Revenue Interest Agreement [Member] | HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Cumulative payments |
|
49,500,000
|
|
$ 140,900,000
|
|
$ 140,900,000
|
|
|
|
|
|
Convertible Note Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Notes converted in to common stock, amount | shares |
|
|
|
|
|
63.0731
|
|
|
|
|
|
Notes converted in to common stock, shares |
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
Notes, conversion price per share | $ / shares |
|
|
|
$ 15.85
|
|
$ 15.85
|
|
|
|
|
|
Term Loan [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount |
|
15,000,000
|
|
|
|
|
|
|
|
|
|
Debt issuance costs |
|
|
|
$ 6,800,000
|
|
$ 6,800,000
|
|
|
|
|
|
Contractual interest expense |
|
|
|
$ 3,700,000
|
|
$ 5,800,000
|
|
|
|
|
|
Debt discount and issuance costs amortized to interest expense, amortization period |
|
|
|
|
|
4 years
|
|
|
|
|
|
Expected life |
|
|
|
|
|
4 years
|
|
|
|
|
|
Debt instrument interest rate |
|
|
|
17.86%
|
|
17.86%
|
|
|
|
|
|
Interest expense on debt |
|
|
|
$ 4,300,000
|
|
$ 6,700,000
|
|
|
|
|
|
Amortization of debt issuance cost |
|
|
|
600,000
|
|
900,000
|
|
|
|
|
|
6% Convertible Senior Notes Due 2029 [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount |
|
111,000,000
|
|
|
|
|
|
|
|
|
|
6% Convertible Senior Notes Due 2029 [Member] | HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount |
|
5,000,000
|
|
|
|
|
|
|
|
|
|
Credit Agreement and Term Loan [Member] | Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents and investments |
|
|
|
25,000,000
|
|
25,000,000
|
|
|
|
|
|
Line of credit facility |
|
|
|
|
|
|
|
$ 100,000,000
|
|
|
|
2029 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount |
$ 5,000,000
|
|
|
116,000,000
|
|
116,000,000
|
|
|
|
|
|
Debt issuance costs |
|
|
|
4,758,000
|
|
4,758,000
|
|
|
|
|
|
Contractual interest expense |
|
|
|
1,700,000
|
|
$ 2,700,000
|
|
|
|
|
|
Debt discount and issuance costs amortized to interest expense, amortization period |
|
|
|
|
|
5 years
|
|
|
|
|
|
Notes, interest rate |
|
|
|
|
|
6.00%
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
|
$ 111,000,000
|
|
|
|
|
|
Notes conversion price, percentage |
|
|
|
|
|
130.00%
|
|
|
|
|
|
Notes instrument, trading days | Days |
|
|
|
|
|
20
|
|
|
|
|
|
Debt instrument convertible threshold consecutive trading days | Days |
|
|
|
|
|
30
|
|
|
|
|
|
Percentage of redeem notes at premium with proceeds |
|
|
|
|
|
101.00%
|
|
|
|
|
|
Estimated fair value of convertible notes |
|
|
|
$ 87,200,000
|
|
$ 87,200,000
|
|
|
|
|
|
Debt instrument interest rate |
|
|
|
26.94%
|
|
26.94%
|
|
|
|
|
|
Long-term debt gross |
|
|
|
$ 148,132,000
|
|
$ 148,132,000
|
|
|
|
|
|
Gain on extinguishment of debt |
|
|
|
|
|
44,700,000
|
|
|
|
|
|
Initial fair value |
|
|
|
78,900,000
|
|
78,900,000
|
|
$ 78,900,000
|
|
|
|
Initial fair value adjustment |
|
|
|
|
|
32,100,000
|
|
|
|
|
|
Bifurcation of embedded derivatives |
|
|
|
28,900,000
|
|
28,900,000
|
|
|
|
|
|
Interest expense on debt |
|
|
|
3,500,000
|
|
5,500,000
|
|
|
|
|
|
Amortization of debt issuance cost |
|
|
|
$ 1,800,000
|
|
$ 2,800,000
|
|
|
|
|
|
2029 Notes [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Percentage common stock outstanding |
|
|
|
19.99%
|
|
19.99%
|
|
|
|
|
|
2029 Notes [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Percentage common stock outstanding |
|
|
|
4.99%
|
|
4.99%
|
|
|
|
|
|
2029 Notes [Member] | HealthCare Royalty Partners IV LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount |
5,000,000
|
|
|
|
|
|
|
|
|
|
|
2029 Notes [Member] | Convertible Note Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Notes converted in to common stock, amount | shares |
|
|
|
|
|
444.4444
|
|
|
|
|
|
Notes converted in to common stock, shares |
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
|
$ 111,000,000
|
|
|
|
|
|
Notes, conversion price per share | $ / shares |
|
|
|
$ 2.25
|
|
$ 2.25
|
|
|
|
|
|
2025 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount |
|
$ 24,500,000
|
|
$ 24,500,000
|
|
$ 24,500,000
|
|
|
172,500,000
|
|
$ 172,500,000
|
Debt issuance costs |
|
|
|
5,600,000
|
|
5,600,000
|
|
|
|
|
|
Contractual interest expense |
|
|
|
184,000
|
1,293,000
|
$ 2,170,000
|
3,881,000
|
|
|
|
|
Debt discount and issuance costs amortized to interest expense, amortization period |
|
|
|
|
|
7 years
|
|
|
|
|
|
Notes, interest rate |
|
|
|
|
|
3.00%
|
|
|
|
|
|
Notes, maturity date |
|
|
|
|
|
Oct. 15, 2025
|
|
|
|
|
|
Principal amount of notes used in conversion rate |
|
|
|
1,000
|
|
$ 1,000
|
|
|
|
|
|
Debt instrument, convertible latest date |
|
|
|
|
|
Jun. 15, 2025
|
|
|
|
|
|
Notes conversion price, percentage |
|
|
|
|
|
130.00%
|
|
|
|
|
|
Notes instrument, trading days | Days |
|
|
|
|
|
20
|
|
|
|
|
|
Debt instrument convertible threshold consecutive trading days | Days |
|
|
|
|
|
30
|
|
|
|
|
|
Notes, repurchase price |
|
|
|
|
|
100.00%
|
|
|
|
|
|
Estimated fair value of convertible notes |
|
|
|
$ 19,200,000
|
|
$ 19,200,000
|
|
|
$ 87,900,000
|
|
|
Expected life |
|
|
|
|
|
7 years
|
|
|
|
|
|
Debt instrument interest rate |
|
|
|
3.53%
|
|
3.53%
|
|
|
|
|
|
Long-term debt gross |
|
|
|
$ 25,604,000
|
|
$ 25,604,000
|
|
|
|
|
|
Interest expense on debt |
|
|
|
217,000
|
1,498,000
|
2,518,000
|
4,478,000
|
|
|
|
|
Amortization of debt issuance cost |
|
|
|
$ 33,000
|
$ 205,000
|
$ 348,000
|
$ 597,000
|
|
|
|
|
2025 Notes [Member] | Convertible Note Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Notes converted in to common stock, shares |
$ 148,000,000
|
|
|
|
|
|
|
|
|
|
|